February 2013 FDA Recall Drug by Sanofi-synthelabo
D-886-2013 - Subpotent Drug

This Class II drug recall was voluntarily initiated by Sanofi-synthelabo on February 26, 2013 for the product Drug. The FDA reported the reason for recall as subpotent drug. The product was distributed in Canada and the recall is currently terminated.

Recall Number: D-886-2013

Reason for Recall
Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.
Initiated
02-26-2013
Reported
08-21-2013
Quantity
998 Bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887

Batch or Lot Expiration Information

Lot# 3099036, Exp 03/2014